Local Students show off skills at Odyssey of the Mind
Teams who placed first place or, for a few teams who held advancing positions in second place — will be headed for New York State Competition in Syracuse at the Syracuse Fairgrounds on Saturday, April 5. For teams going to the New York State Competition in Syracuse, spectators will be welcome and more information can be found on the NY Odyssey of the Mind's State Finals webpage.
2024 Odyssey of the Mind winners
Problem #1 – Division I – The OM-Mazing Race –
Third Place – Copenhagen Central School
Second Place – Sackets Harbor Central School – Advancing
First Place – Mannsville Elementary School – Advancing
Problem #2 – Division 1 – Mech-Animal Sidekick
Second Place – Lura Sharp Elementary School – Advancing
First Place – Beaver River Central School – Advancing
Problem #3 – Division I – Cooking With Books
First Place – Beaver River Central – Advancing
Problem #3 – Division II – Cooking With Books
Second Place – Sackets Harbor
First Place – South Lewis Central – Advancing
Problem 3 – Division III – Cooking With Books
Second Place – Park United Methodist Church – Advancing
First Place – Beaver River Central School – Advancing
Problem 4 – Division I – Save Me Structure
First Place – Lura Sharp Elementary – Advancing
Problem 5 – Astronomical Odyssey – Division 1
Third Place – Lowville –
Second Place – Mannsville Elementary – Advancing
First Place – Sackets Harbor – Advancing
Problem 5 – Astronomical Odyssey – Division II
First Place – Beaver River
Problem 5 – Astronomical Odyssey – Division III
First Place – South Lewis Central
Additional Awards:
One OMER Award was given to the South Lewis Problem 5, Division III Team.
One OMER Award was given to Beaver River Central School – Division III Team
One OMER Award was given to Lowville Academy and Central School – Division 1 Team
One Renatra Fusca Creativity Award was given to Abby Swadowski from South Lewis
Results are posted on the NY Odyssey of the Mind website and you can view the total scores there.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...
Research and Development Expenses: $2.1 million for Q2 2025, compared to $15.1 million for Q2 2024. General and Administrative Expenses: $8.6 million for Q2 2025, compared to $7.3 million for Q2 2024. Net Loss: $26.9 million or $0.9 per share for Q2 2025, compared to $20.9 million or $0.9 per share for Q2 2024. Cash and Cash Equivalents: $312.8 million as of June 30, 2025. Follow-on Financing Proceeds: $230 million from May 2025, including full exercise of underwriters' option. Refinanced Loan: New debt facility of $50 million upfront with Trinity Capital, deferring principal payments by over 2.5 years. Warning! GuruFocus has detected 4 Warning Signs with TSHA. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Taysha Gene Therapies Inc (NASDAQ:TSHA) has obtained alignment with the FDA and Health Canada to proceed with initiating their REVEAL pivotal trial for TSHA-102, indicating strong regulatory progress. The company reported positive clinical data supporting the therapeutic potential of TSHA-102, with all 10 patients in Part A of the REVEAL trials gaining or regaining developmental milestones. TSHA-102 is designed to target the genetic root cause of Rett syndrome, leveraging a clinically proven AAV9 vector and a minimally invasive lumbar intrathecal injection method. The company completed a public follow-on offering, resulting in total gross proceeds of $230 million, extending their cash runway into 2028. Taysha Gene Therapies Inc (NASDAQ:TSHA) has a defined path to registration for TSHA-102, with a pivotal trial underway and a strengthened balance sheet. Negative Points The company reported a net loss of $26.9 million for the three months ended June 30, 2025, compared to a net loss of $20.9 million for the same period in 2024. General and administrative expenses increased to $8.6 million for the three months ended June 30, 2025, primarily due to higher legal and professional fees. There are no currently approved therapies that treat the underlying genetic root cause of Rett syndrome, highlighting the urgency and challenge of developing effective treatments. The company faces risks and uncertainties that may cause actual results to differ materially from forward-looking statements, as noted in their SEC filings. The pivotal trial design relies on a novel regulatory pathway, which may present challenges in terms of regulatory approval and market acceptance. Q & A Highlights Q: Given there was a 100% response rate for the pivotal trial primary endpoint in Part A of the study, is this the bar for Part B in your view? A: Sean Nolan, CEO: The results from Part A are compelling, but maintaining a 100% response rate is challenging. The statistical plan for Part B uses a null hypothesis of 6.7%, meaning only 1 out of 15 patients might spontaneously gain or regain a milestone. The statistical bar is relatively low, around 33%, and the numbers from Part A are significantly above this threshold. Q: Are there certain time points where all milestones are occurring, or are additional ones seen over time? Have the benefits of the gene therapy plateaued? A: Elsa Rosignol, Director of Integrated Rett Syndrome Clinic: We see increasing improvements over time, not just at one visit. Gains occur at most follow-up visits, and some critical gains in daily functioning are not captured in the developmental milestone assessment but are still significant improvements. Q: How does your gene therapy differentiate from competitors, particularly regarding study design and primary endpoints? A: Sean Nolan, CEO: Our approach is unique, focusing on clinically meaningful and objective gains in activities of daily living. We've worked with regulators to establish a new paradigm in assessing clinical efficacy through milestone gains. This approach is supported by KOLs, advocacy groups, and regulators, emphasizing the therapy's impact on quality of life. Q: Would you expect any pushback on using your interim readout to support BLA filing, given your competitor's feedback on a 6-month endpoint? A: Sean Nolan, CEO: Our interim analysis approach is data-driven, based on robust support from Part A data. We've discussed this with the FDA, focusing on further refinements of the analysis rather than overturning key trial design elements. We feel confident about our position. Q: Can you characterize any changes from Part A CMC material batch to Part B, specifically regarding full to empty capsid ratio? How many patients can you supply with commercial-scale material? A: Sean Nolan, CEO: We've aligned with the FDA that Part A and pivotal material are analytically comparable. We've made the product for the pivotal trial with the commercial process at scale. Our cash runway into 2028 allows us to build commercial inventory as needed, ensuring we're well-positioned on the CMC side. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Residents evacuate amid urgent warnings glacial lake will flood city
Juneau, Alaska's capital, is bracing for what authorities warn could be record-breaking floodwaters, as a glacial outburst from the Mendenhall Glacier threatens sections of the city. Residents in affected areas have begun evacuating, heeding urgent warnings. The deluge, caused by rainwater and snowmelt accumulating behind a basin dammed by the Mendenhall Glacier, began escaping the ice dam Tuesday morning. Flooding is anticipated to continue into Wednesday, impacting homes situated along the Mendenhall River and near Mendenhall Lake. The Mendenhall Glacier, a popular tourist attraction, lies about 12 miles (19 kilometers) from Juneau, a city of 30,000 people. Its proximity means that many properties on the city's outskirts are directly in the path of the glacial outburst. The National Weather Service predicts the flooding will peak between 8am and noon Wednesday. Nicole Ferrin, a meteorologist with the service, said: "This will be a new record, based on all of the information that we have." Flooding from the basin has become an annual concern since 2011, and in recent years has swept away houses and swamped hundreds of homes. Government agencies installed temporary barriers this year in hopes of protecting several hundred homes in the inundation area from widespread damage. The flooding happens because a smaller glacier near Mendenhall Glacier retreated — a casualty of the warming climate — and left a basin that fills with rainwater and snowmelt each spring and summer. When the water creates enough pressure, it forces its way under or around the ice dam created by the Mendenhall Glacier, enters Mendenhall Lake and eventually flows down the Mendenhall River, as it did Tuesday. Before the basin began overtopping, the water level was rising rapidly — as much as 4 feet (1.22 meters) per day during especially sunny or rainy days, according to the National Weather Service. The city saw successive years of record flooding in 2023 and 2024 — with the river last August cresting at 15.99 feet (4.9 meters), about 1 foot (30 centimeters) over the prior record set a year earlier — and flooding extending farther into the Mendenhall Valley. This year's flooding was predicted to crest at between 16.3 and 16.8 feet (4.96 to 5.12 meters). In 2024, nearly 300 homes were damaged. A large outburst can release some 15 billion gallons of water, according to the University of Alaska Southeast and Alaska Climate Adaptation Science Center. That is the equivalent of nearly 23,000 Olympic-size swimming pools. During the 2024 flood, the flow rate in the rushing Mendenhall River was about half that of Niagara Falls, the researchers say. City officials responded to concerns from property owners this year by working with state, federal and tribal entities to install a temporary levee along roughly 2.5 miles (4 kilometers) of riverbank in an attempt to guard against widespread flooding. The 10,000 'Hesco' barriers are essentially giant sandbags intended to protect more than 460 properties completely during an 18-foot (5.5-meter) flood event, said emergency manager Ryan O'Shaughnessy. The U.S. Army Corps of Engineers is at the start of what is expected to be a years-long process of studying conditions in the region and examining options for a more permanent solution, such as a levee. The timeline has angered some residents, who say it is unreasonable. Outburst floods are expected to continue as long as the Mendenhall Glacier acts as an ice dam to seal off the basin, which could span another 25 to 60 years, according to the university and science center researchers.
Yahoo
13 minutes ago
- Yahoo
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ...
Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Theravance Biopharma Inc (NASDAQ:TBPH) reported a strong quarter with net sales reaching approximately $66 million, driven by demand growth and favorable pricing. The company completed a $225 million sale of its remaining royalty interests in Trilogy to GSK, significantly strengthening its balance sheet. The phase 3 Cypress trial for amproloxetine is progressing well, with enrollment nearing completion and top-line data expected in six months. Theravance Biopharma Inc (NASDAQ:TBPH) ended the quarter with approximately $340 million in cash and no debt, maintaining a strong financial position. The company is on track to achieve significant milestones, including a potential $150 million from royalty Pharma over the next 18 months. Negative Points The company did not provide guidance on the formal launch timing for Upellry in China, as Beatrice is still finalizing the commercialization plan. There is uncertainty regarding the pricing strategy for amproloxetine, as it is still early to determine a specific price point. The company faces challenges in ensuring proper education for clinicians to make the best decisions for patient needs, particularly in specialty pharmacy channels. Theravance Biopharma Inc (NASDAQ:TBPH) expects to pay approximately $27 million in taxes related to the Trilogy royalty sale in the second half of the year. There is potential for pushback on amproloxetine pricing and reimbursement, given the presence of generics with less efficacy and clear side effects. Q & A Highlights Warning! GuruFocus has detected 7 Warning Signs with TBPH. Q: What factors contributed to the improved pull-through performance for Upellary this quarter? A: Rhonda Farnham, Chief Business Officer, explained that the improved pull-through was driven by the transition of volume to specialty pharmacy, which enhances pricing and persistency. The support patients receive in this channel improves fulfillment and persistency compared to conventional retail pharmacy. The company remains focused on providing options that best meet individual patient needs while educating clinicians to make informed decisions. Q: Can you provide an update on the outlook for Upellary's growth in China and the Cyprus trial enrollment? A: Rhonda Farnham stated that Beatrice is leading the commercialization efforts in China, and further details will be shared once their market plan is unveiled. Anya Miller, Head of Development, noted that the Cyprus trial's US versus ex-US enrollment is expected to mirror previous studies, with all data to be disclosed at the topline readout. A press release will be issued upon full enrollment of the open-label portion. Q: How is Theravance Biopharma approaching the pricing strategy for amproloxetine, and what are the considerations for reimbursement in the US? A: Rhonda Farnham mentioned that while it's early to finalize pricing, an analysis of recent rare neuro drug launches suggests an average price of approximately $380,000 per year. The company is actively engaging with payers to highlight the unmet need and the potential benefits of amproloxetine, focusing on its safety profile and durability of effect. Q: What are the expectations for SG&A expenses related to amproloxetine's commercialization, and how might they change post-data readout? A: Aziz Sala, Chief Financial Officer, indicated that SG&A expenses are expected to remain stable through the year, with some pre-launch activities already underway. Post-data readout, if positive, there will be an increase in SG&A spend, but it will be targeted and not excessively large, focusing on supporting the launch and marketing efforts. Q: Can you elaborate on the operating leverage observed in the collaboration revenue growth compared to Upellary's net sales increase? A: Aziz Sala explained that the collaboration revenue growth outpaced net sales growth due to cost reimbursements between the companies. While this quarter showed a significant gap, future quarters may not see the same level of disparity. However, profit margins are expected to continue improving as net sales grow. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
